-
Insilico Medicine Closes USD95m Series D Financing to Advance AI Drug Discovery
•
Insilico Medicine, a Hong Kong-based artificial intelligence (AI)-driven drug discovery company, announced the closure of a USD95 million Series D financing round following Series D2 funding. The round was led by Saudi Aramco’s Prosperity7 Ventures. The proceeds will be used to advance its in-house developed product pipeline and accelerate pivotal…
-
Ningbo Health Gene Raises Hundreds of Millions in Series C Financing
•
Ningbo Health Gene Technologies Co., Ltd, a China-based medical testing solution provider, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round led by SCGC. Other investors included BioTrack Capital, Hefeng Venture Capital, Yingong Venture Capital, and Binjiang Xincheng Development Investment. The proceeds will be directed…
-
Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round
•
Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33 million on top of a USD100 million Series B financing round in October last year. The expanded funding included new investors such as Deep Track Capital and Piper Heartland Healthcare Capital. Proceeds will support key…
-
Fosun Pharma’s Proxima AI Raises Over RMB 100M in Strategic Financing
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Proxima AI Technology Co., Ltd has reportedly raised over RMB 100 million (USD 14.8 million) in a strategic financing round. The round was led by Fosun Pharma and Guoyao Zhongjin (Shanghai) Medical Health Investment Management, with Anting Industrial…
-
Taibang Biologic Raises $300M in Post-Privatization Financing Round
•
Taibang Biologic Group (NASDAQ: CBPO), a plasma specialist privatized by Centurium Capital in April 2021, is set to raise $300 million in its first financing round since the deal. The round, led by Abu Dhabi Investment Authority’s (ADIA) subsidiary Platinum Orchid and Government of Singapore Investment Corp (GIC), includes participation…
-
Sironax Completes $200 Million Series B Financing for Age-Related Disease Therapies
•
Beijing-based clinical-stage biotechnology company Sironax announced the completion of a $200 million Series B financing round. The funding will support the clinical development of its receptor interacting protein kinase 1 (RIPK1) inhibitor and expansion of its R&D pipeline targeting age-related degenerative diseases. Funding Round DetailsThe financing round was led by…
-
Tus-Pharma to Acquire Sinotau Pharma for RMB 220 Million
•
China-based Tus-Pharmaceutical Group Co., Ltd (SHE: 000590) has announced plans to acquire 100% of Guangdong Sinotau Pharmaceutical Co., Ltd for RMB 220 million (USD 32.6 million) in cash. The deal aims to expand Tus-Pharma’s manufacturing footprint and product portfolio. Transaction DetailsSinotau Pharma owns a 14,496 sq.m factory with three production…
-
China Resources Double-Crane to Acquire Stake in Shenzhou Biotech for Bio-Fermentation Push
•
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced plans to acquire a 50.11% stake in Shenzhou Biotechnology Co., Ltd for RMB 501.73 million (USD 74.1 million). The move aims to expand the firm’s presence in the bio-fermentation sector. Transaction DetailsThe acquisition will give Double-Crane a controlling interest in Shenzhou…
-
Coherent Biopharma Raises Series B Funds to Advance Bi-XDC Pipeline
•
Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), has reportedly raised an undisclosed amount in a Series B financing round. The funding was led by HM Capital and included participation from Suzhou Yuanfeng Capital, ABC International, V-Capital, and existing investor 6 Dimensions Capital. Company ProfileCoherent Biopharma leverages…
-
OriginCell Therapeutics Raises USD 120M in Series B for Tumor Immunotherapy Pipeline
•
OriginCell Therapeutics, a Shanghai-based tumor immunotherapy specialist, reportedly raised over USD 120 million in a Series B financing round. The round was co-led by Qiming Venture Partners and Quan Capital, with participation from Shanghai Science and Technology Innovation Center Equity Investment Fund, Sinopharm Capital, Suzhou Fund, Boquan Equity Investment Management,…
-
Fosun Pharma to Hike Aitrox Stake to 72.63% for USD 61M
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) plans to increase its ownership of Aitrox from 28.23% to 72.63% in a deal valued at RMB 412.35 million (USD 61 million). The investment includes a direct capital injection of RMB 50 million (USD 7.4 million) and the acquisition of…
-
GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline
•
GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly raised USD 22 million in a Series A+ financing round. The round brings the company’s total funding to USD 90 million since its founding in March 2023. Existing investor Qiming Venture Partners led the round,…
-
BridGene Biosciences Completes USD 38.5M Series B Round with China Funds
•
U.S.-based biotech BridGene Biosciences Inc. has completed a Series B financing round, raising USD 38.5 million. The round was backed by China-based funds, including Beijing’s Lapam Capital, Hong Kong’s Junson Capital, and Xiamen’s Dyee Capital. Funding UseProceeds will support the development of BridGene’s proprietary chemoproteomic platform IMTAC, including clinical trials…
-
Kolo Medical Raises RMB 100M in Series B2 to Launch High-Frequency Ultrasound Imaging System
•
Suzhou-based Kolo Medical Inc., a leader in next-generation semiconductor ultrasound CMUT (Capacitive Micromachined Ultrasonic Transducer) chip technology, has raised nearly RMB 100 million (USD 14.8 million) in a Series B2 financing round. The round was led by Qianrong Investment and included participation from Walden International. Funding UseProceeds from the funding…
-
Wanbangde Pharmaceutical to Acquire Consun Pharma Shares in RMB 2.2B Deal
•
China-based Wanbangde Pharmaceutical Group has entered into a non-legally binding letter of intent with Consun Pharmaceutical Group Ltd (HKG: 1681) to acquire 238,056,948 shares at RMB 9.17 (USD 1.36) per share, valuing the transaction at approximately RMB 2.2 billion (USD 325 million). About Consun PharmaceuticalConsun Pharma, listed on the Hong…
-
Legend Biotech Plans USD 250M Secondary Offering to Fund CAR-T Therapy Development
•
China-based Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T cell therapy, announced plans to raise USD 250 million through a secondary public offering of American Depositary Shares (ADSs). Each ADS represents two ordinary shares. The underwriters have a 30-day option to purchase an additional USD…
-
MobiDrop Raises USD 14.8M in Series A+ to Expand Single-Cell Product Pipeline
•
China-based MobiDrop (Zhejiang) Co., Ltd has reportedly raised close to RMB 100 million (USD 14.8 million) in a Series A+ financing round led by LYFE Capital. Existing investor Source Code Capital and a government-led fund also participated. Funding UseProceeds will support the expansion of MobiDrop’s single-cell product pipeline, research and…
-
ZGC Shuimu Medtech Raises RMB 100M in Series A+ Round Led by Yijing Capital
•
Beijing-based ZGC Shuimu Medical Technology Services Group, China’s first private third-party medical device testing institution, has reportedly raised RMB 100 million (USD 18.8 million) in a Series A+ financing round. The round was led by Yijing Capital and Green Pine Capital Partners. This follows the company’s Series A financing round…
-
Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001
•
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced plans to raise RMB 270 million (USD 51.4 million) through a private placement to support the development of its COVID-19 drug candidate FB2001. The funding will be used for a Phase I clinical study, global Phase II/III trials, and quality and process studies.…
